SAGE
Sage Therapeutics Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
sage therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare cns disorders. our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. to achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. sage’s lead program, sage-547, is in clinical development for super-refractory status epilepticus (srse) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. sage’s robust chemistry platform has generated multiple new compounds that target the gabaa and nmda receptors, which have demonstrated preclinical activity. sage therapeutics is a private company launched in 2010 by an experienced team of r&d leaders, cns experts and investors.
Market Cap: 1.27 Billion
Primary Exchange: NASDAQ
Website: https://www.sagerx.com/
Shares Outstanding: 60.1 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.8222170269841426
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 987 trading days
From: 2018-02-01 To: 2024-03-07
Lowest Point:
BIIB Is For Buy-O-Gen
via: SeekingAlpha at 2019-06-12 06:30:36:000
Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc… read more...
BIIB Is For Buy-O-Gen
via: SeekingAlpha at 2019-06-12 06:30:36:000
Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc… read more...
Stoke Therapeutics Files Proposed Terms For IPO
via: SeekingAlpha at 2019-06-11 08:24:08:000
Quick Take Stoke Therapeutics ( STOK ) has filed to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing therapeutics for severe genetic diseases with a focus on dominant loss-of-function [haploinsufficient] diseases of … read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|